For many women, miscarriage is a silent heartbreak—a traumatic experience often dismissed as mere bad luck. The emotional toll of pregnancy loss can be devastating, especially when it happens repeatedly. Traditionally, women who experience miscarriage are told it’s a matter of “bad luck,” and many never receive a clear reason for their loss. But new research is changing that narrative, offering hope to women who long for answers—and for a healthy pregnancy.

A recent study published in Science Advances has revealed that an experimental test can predict a woman’s risk of miscarriage by identifying problems in the womb lining before pregnancy even begins. This innovation not only promises to transform how we understand miscarriage but also opens the door to targeted treatments that could help prevent it.

How Does The Test Work?

The process of preparing the womb lining (endometrium) for implantation is called the "decidual reaction." This process enables the endometrium to morph into a receptive environment for embryo implantation. When this transformation doesn’t progress adequately, it can lead to pregnancy loss.

Researchers analyzed over 1,500 biopsies from more than 1,300 women to study the decidual reaction during menstrual cycles. They found that a stalled or abnormal reaction reduced the likelihood of a live birth by 48% to 58%. More importantly, this problem recurred in some women across multiple cycles, suggesting a consistent, underlying cause rather than random chance.

Researchers found that abnormalities in this process can increase miscarriage risk, and that a prior miscarriage significantly raises the odds of such abnormalities in future menstrual cycles. These findings suggest that recurrent miscarriages are not necessarily random or purely genetic but could be linked to persistent issues with the womb lining.

The test is designed to detect whether the endometrium is ready for pregnancy by evaluating specific biological markers. If the reaction is abnormal, targeted treatments can be offered before conception, increasing the chances of a successful pregnancy.

Dr. Joanne Muter, lead investigator of the study, states, “Many women are told they’ve just had 'bad luck', but our findings show that the womb itself may be setting the stage for pregnancy loss, even before conception takes place.”

Link Between Previous Miscarriages and Future Risk

One of the study’s most significant findings is that a prior miscarriage can increase the odds of abnormal womb lining responses in future menstrual cycles. This explains why some women experience multiple miscarriages: the underlying issue may persist from one cycle to the next, making each new pregnancy vulnerable to the same fate.

Senior researcher Professor Jan Brosens explains, “This study shows that each miscarriage increases the risk of an embryo implantation in an abnormal womb lining, regardless of age.” Chromosomal errors in embryos remain a factor, but the health of the womb lining is now recognized as a critical, and potentially preventable, contributor to pregnancy loss.

Holly Milikouris and her husband Chris were nearly resigned to a future without children after five unexplained miscarriages. "Being given the opportunity to take part in this trial was life changing," she says. The test identified that her womb was not adequately preparing for pregnancy. After targeted treatment, Holly now has a three-year-old son George and a 17-month-old daughter Heidi.

Dr. Tajinin Islam, a psychiatrist from Chester, also participated in the trial after several failed pregnancies. Today, she is the proud mother of a 16-month-old son, Mivaan. “If I can have a baby over 40, then other women with my condition can too,” she affirms.

Until now, miscarriage has often been attributed to genetic abnormalities in the embryo. While chromosomal errors do account for some cases, this research emphasizes the role of the maternal environment. According to Brosens, “The frequency of one of two events — abnormal embryo or abnormal decidual reaction — determines miscarriage likelihood. We now have the tools to screen for risk and improve womb conditions before pregnancy.”

How It Aligns With Early Fetal Development Monitoring?

The earliest stages of fetal development are delicate and require a stable, supportive environment. From the moment of conception, the embryo relies on the womb lining for nutrients and protection. If the endometrium is not properly prepared, the risk of bleeding and pregnancy loss increases—even if the embryo implants successfully.

Doctors use a combination of blood tests (to monitor hCG and progesterone levels) and ultrasounds to track early fetal development. These tests help confirm that the pregnancy is progressing as expected, but until now, there was no way to assess the womb’s readiness before conception.

The diagnostic test based on this research is already being used in clinical care, with over 1,000 patients benefiting from its insights. By identifying women at risk before pregnancy, doctors can offer targeted therapies—such as hormonal treatments or interventions to improve the endometrial environment—potentially preventing miscarriage before it happens.

Lead investigator Dr. Joanne Muter emphasizes, “This is about identifying preventable miscarriages. Many women are told they’ve just had ‘bad luck’, but our findings show that the womb itself may be setting the stage for pregnancy loss, even before conception takes place.”

Miscarriage will always be a complex and deeply personal experience, but advances like this new test are bringing us closer to understanding—and preventing—many cases of pregnancy loss.

With rates of esophageal cancer having quadrupled since the 1970s and fewer than 20% of patients surviving five years post-diagnosis, early detection is more critical than ever. The capsule sponge test offers a powerful tool for risk stratification, ensuring that high-risk individuals continue receiving endoscopy while sparing low-risk patients from unnecessary invasive procedures.

The gold standard for monitoring patients at risk of esophageal (throat) cancer has been the endoscopy—a procedure that, while effective, is invasive, uncomfortable, and resource-intensive. Now, a simple device known as the “pill-on-a-string” or capsule sponge test is emerging as a transformative alternative, promising to make screening and surveillance for throat cancer faster, less invasive, and more accessible for millions worldwide.

The concept is ingeniously simple: patients swallow a small capsule attached to a string. Once in the stomach, the capsule dissolves, releasing a sponge that expands to about the size of a coin. Healthcare professionals then gently pull the sponge back up by the string, allowing it to collect cells from the lining of the esophagus as it travels upward. The entire procedure takes about ten minutes and can be performed by a nurse in a clinic or even a mobile screening van.

Barrett’s esophagus is a chronic condition in which prolonged acid reflux damages the lining of the esophagus. Over time, the damaged cells can become precancerous, forming dysplasia, and potentially progressing into esophageal adenocarcinoma—a type of throat cancer with notoriously poor survival rates. Despite the relatively low annual conversion rate from Barrett’s to cancer (approximately 0.5%), regular monitoring is essential.

Traditionally, endoscopy has been the go-to method for this surveillance. However, it is not without drawbacks: sedation, fasting, potential complications, and significant cost. This is where the pill-on-a-string method is poised to transform care—making monitoring more accessible, efficient, and patient-friendly.

What Is the Pill-on-a-String Test?

The new test involves swallowing a capsule containing a compressed sponge. Once it reaches the stomach, the capsule dissolves, allowing the sponge to expand. Attached to a string, the sponge is gently pulled back up through the esophagus, collecting cells from the lining along the way. These cells are then analyzed in a lab for red-flag changes indicative of dysplasia or early cancer.

Though the idea may initially sound uncomfortable, the experience has proven to be far more tolerable than an endoscopy. For Duncan Cook, a 57-year-old heating engineer from Cambridge, who has endured nearly two decades of endoscopic monitoring, the change was welcome.

“The first time I had the sponge, I was a bit nervous,” Cook shared in a news release. “It’s quite a big pill to swallow, but it’s much better than going for endoscopies... I was able to have the test done and go right back to work after.”

A major challenge is that symptoms often overlap with benign conditions like heartburn, leading to late diagnoses when treatment options are limited. Early detection is critical: when caught at stage 1, five-year survival rates can reach 63%. This is why regular surveillance of high-risk individuals—particularly those with Barrett’s esophagus—is so important.

In a large multi-center trial involving 910 patients across 13 hospitals in the U.K., researchers from the University of Cambridge and Queen Mary University of London evaluated the effectiveness of the capsule sponge test. Participants—all of whom were already being monitored for Barrett’s esophagus—underwent both the new test and a standard endoscopy for comparison. Findings from the study, recently published in The Lancet, are compelling:

• 54% of patients were classified as low-risk after the sponge test, showing no cellular changes that could indicate progression to cancer.
• Only 0.4% of the low-risk group were later found via endoscopy to have high-risk cell changes.
• No cancers were detected in those flagged as low-risk by the sponge test.

These results suggest that more than half of the patients undergoing routine endoscopies could safely switch to the capsule test without compromising diagnostic accuracy.

“Our findings suggest that the capsule sponge could help stratify patients with Barrett’s esophagus by risk,” said Dr. Peter Sasieni, director of the Cancer Research UK Cancer Prevention Trials Unit. “Given the low risk of progression in these individuals, it should be safe to replace their usual endoscopy with the capsule sponge.”

The research team isn’t stopping here. Scientists are now working to refine the sponge test further by enhancing laboratory analysis of the collected cell samples. Artificial intelligence (AI) is being evaluated to assist in identifying early signs of dysplasia, potentially boosting accuracy and reducing human error.

Professor Rebecca Fitzgerald, director of the Early Cancer Institute at Cambridge, noted, “We need an alternative surveillance method that’s less invasive, easier to administer and more reliable… Endoscopies aren’t always a reliable way of spotting early cancers, and they depend on the skill of the person doing it."

Food Standards Australia New Zealand is urging people to not consume two peanut butter products by Coles. These two varieties are Coles Smooth peanut butter and Coles Crunchy peanut butter, which have been found to contain mycotoxin and aflatoxin. Coles has also recalled these two products. The question is raised for products with the batch marked best before February 5, 2027.

Coles' recalling means that people can return these products for a full refund.

The toxins found in these products are said to increase the risk of liver cancer. An alert has been issued, which reads: “Coles Online customers can receive a refund or credit by contacting Coles Online Customer Care on 1800 455 400. Any consumers concerned about their health should seek medical advice.”

Also Read: Hepatitis B Nears Elimination In Uzbek Children After Years Of Immunization

What Are These Toxins, How Does It Impact Our Health?

Mycotoxins

As per the World Health Organization (WHO), mycotoxins are toxic substances produced naturally by certain types of mould (fungi). These moulds can grow on a wide variety of foods—such as grains, dried fruits, nuts, and spices—especially in warm, damp, and humid environments. The contamination can occur either before harvest or after, during storage or even on the food itself. Alarmingly, most mycotoxins are highly stable and can survive food processing methods.

There are hundreds of known mycotoxins, but a few pose significant health risks to both humans and animals. These include aflatoxins, ochratoxin A, patulin, fumonisins, zearalenone, and nivalenol/deoxynivalenol. Mycotoxins enter the food chain when crops are infected with mould. People can be exposed either by consuming contaminated food directly or indirectly—most commonly through animal products like milk, when livestock are fed mould-contaminated feed.

Where Are They Found?

Mycotoxins can contaminate food before harvest (in the field) or afterward during storage and processing. Since most mycotoxins are chemically stable, they can survive food manufacturing and cooking processes, making them hard to eliminate completely.

Mycotoxins can pose serious health risks to both humans and animals. Their effects can range from sudden poisoning to long-term health issues such as:

• Suppressed immune response
• Liver damage
• Increased cancer risk

Livestock can also be exposed through contaminated feed, and humans may indirectly consume these toxins through animal products like milk.

Also Read: 'Who Heals The Healer?' What Makes The National Doctors' Day 2025 Theme So Relevant?

Common Mycotoxins to Watch For

Though hundreds of mycotoxins have been identified, a few are especially harmful and frequently found in food:

• Aflatoxins (among the most toxic, produced by Aspergillus moulds found in soil and stored grains)
• Ochratoxin A
• Patulin
• Fumonisins
• Zearalenone
• Nivalenol/Deoxynivalenol (DON)

What Are Aflatoxins?

As per the National Cancer Institute, US, aflatoxins are a group of toxic compounds produced by specific types of fungi, primarily Aspergillus flavus and Aspergillus parasiticus. These fungi thrive in warm, humid climates and commonly infect crops like maize (corn), peanuts, cottonseed, and various tree nuts. Contamination can occur at multiple stages—while the crops are growing in the field, during harvest, or later in storage.

The National Cancer Institute also notes that exposure to aflatoxins is associated with an increased risk of liver cancer.

Another 2013 study published in World Journal of Gastroenterology notes that while Hepatocellular carcinoma (HCC) is one of the leading causes of cancer deaths worldwide, it is caused by aflatoxin. The study notes that aflatoxin is a food contaminant produced by the fungi Aspergillus flavus and Aspergillus parasiticus, is a known human carcinogen that has been shown to be a causative agent in the pathogenesis of HCC. In fact, Aflatoxin B1 has been classified by the WHO as a “group A” carcinogen because of it’s proven contribution to the pathogenesis of HCC.

In 2001, Uzbekistan was far from a model of public health. The country was grappling with high hepatitis B infection rates and a fragmented healthcare system, few would have predicted that it would one day be celebrated for near elimination of the disease in children.

Yet today, reports Gavi, The Vaccine Alliance, the country stands among just nine in the World Health Organization (WHO) European region to meet hepatitis B control targets. A recent nationwide survey revealed that only 0.2% of Uzbek children carry the hepatitis B surface antigen (HBsAg)—well below WHO’s 0.5% threshold.

What is Hepatitis B and Why It’s Dangerous

Hepatitis B is a viral infection that affects the liver. While some infections are brief and symptom-free, others can become chronic, quietly progressing over years to cause liver failure or cancer. The risk of chronic infection is especially high in infants whose immune systems are still developing.

Fortunately, the hepatitis B vaccine is highly effective, offering 98–100% protection after a full three-dose series. WHO recommends that all infants receive the first dose within 24 hours of birth, followed by two or more doses at spaced intervals.

Also Read: National Doctors' Day, July 1, 2025: Theme – "Who Heals the Healer?" Know more about Its History and Significance.

What Are Gavi Countries?

Gavi supports lower-income and transitioning middle-income countries to strengthen immunisation systems and increase vaccine access. Countries that receive support are commonly referred to as “Gavi countries.”

Uzbekistan introduced universal hepatitis B vaccination in October 2001, supported by US$4.5 million in funding from Gavi, the Vaccine Alliance.

From 2001 to 2008, Uzbekistan provided the hepatitis B birth dose followed by two additional doses.

In 2009, the country upgraded to the pentavalent vaccine—offering protection against hepatitis B, diphtheria, tetanus, pertussis, and Haemophilus influenzae type B—while still delivering a standalone birth dose. Gavi extended further funding of US$32 million for the next decade.

Also Read: Healers, But Human Too: The Quiet Burdens Our Doctors Carry

Vaccination coverage has remained impressively high—above 95% since 2002. However, until recently, the real-world impact of the programme on hepatitis B infection rates had not been comprehensively measured.

Proof of Progress In Uzbekistan’s Healthcare

In 2022, a team led by Dr Nino Khetsuriani from the U.S. Centers for Disease Control and Prevention (CDC), along with local researchers, conducted a nationwide survey.

They tested blood samples from 3,753 children in grades one to three and reviewed their immunisation records. Their findings, published in Vaccine, showed that just 0.2% of the children tested positive for HBsAg—proof of the vaccine’s long-term effectiveness.

With consistently high coverage, experts expect the burden of hepatitis B in Uzbekistan to decline further as vaccinated children grow into adulthood, replacing older, unvaccinated cohorts.

Uzbekistan graduated from Gavi’s financial support in 2022. Today, its national immunization programme is fully self-funded and regarded as one of the most efficient in the region.

“Uzbekistan stands as a model of excellence in immunization,” said Jan-Christopher Castilhos França, Gavi’s Senior Country Manager for Middle-Income Countries.